Clinical Trials Pipeline & In-Development

AZD6234

also known as: AZD-6234

AstraZeneca's long-acting amylin analog — Phase 2 in obesity (2024) — part of AZ's entry into the GLP-1-adjacent obesity space alongside ECC5004; analogous in mechanism to cagrilintide.

A long-acting amylin analog peptide in Phase 2 development by AstraZeneca for obesity; mechanistically comparable to cagrilintide and petrelintide, targeting amylin receptors (hybrids of the calcitonin receptor with RAMP1/2/3) to drive satiety and slow gastric emptying independently of GLP-1 agonism.

Mechanism of action

Amylin receptor agonism (calcitonin receptor / RAMP1/2/3 heterodimers) — drives satiety via area postrema and hypothalamic circuits, slows gastric emptying, and suppresses postprandial glucagon. Intended for combination with GLP-1 RAs (the cagrisema / MariTide paradigm).

Primary uses

Obesity (Phase 2)

Typical dosing

once weekly (subcutaneous)

Phase 2 doses not publicly finalized.

Regulatory status

Not approved. Phase 2 in obesity initiated 2024.

References

[manufacturer] AstraZeneca pipeline page — AZD6234 Phase 2 amylin analog.
[clinicaltrials] ClinicalTrials.gov — AZD6234 Phase 2 obesity study.

Related peptides

Cagrilintide

A once-weekly amylin analog developed primarily as a combination partner for semaglutide (CagriSema), adding amylin-pathway appetite suppression to GLP-1 activity.

Petrelintide

Zealand Pharma's amylin monotherapy — ZUPREME-1 Phase 2b hit its endpoints in March 2026 with up to 10.7% weight loss at 42 weeks and "placebo-like" GI tolerability. Roche-partnered since 2025; Phase 3 planned for late 2026.

CagriSema

Novo Nordisk's next-generation obesity injection — NDA filed December 2025, FDA review expected 2026. If approved, it would be the first GLP-1 + amylin fixed-dose combination and a direct competitive response to tirzepatide.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.